MARIBAVIR: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596	NDA	Takeda Pharmaceuticals America, Inc.	64764-800-28	1 BOTTLE in 1 CARTON (64764-800-28) / 28 TABLET, COATED in 1 BOTTLE	2021-11-23
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596	NDA	Takeda Pharmaceuticals America, Inc.	64764-800-56	1 BOTTLE in 1 CARTON (64764-800-56) / 56 TABLET, COATED in 1 BOTTLE	2021-11-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 27, 2025

Introduction

Maribavir, marketed under the brand name Marican, is an antiviral medication indicated primarily for treating refractory cytomegalovirus (CMV) infections in transplant patients. It functions by inhibiting the CMV UL97 kinase enzyme, thereby disrupting viral replication. As a relatively new entrant in the antiviral pharmaceutical landscape, identifying reliable suppliers for Maribavir is crucial for healthcare providers, distributors, and pharmaceutical companies aiming to ensure consistent supply and compliance with regulatory standards. This article examines the key suppliers globally involved in the production and distribution of Maribavir, analyzing their roles, market presence, and strategic significance.

Manufacturers of Maribavir

1. Takeda Pharmaceutical Company

Takeda Pharmaceutical Company, a prominent Japanese multinational, is the original developer and commercializer of Maribavir. Takeda acquired the rights to Maribavir from ViroPharma (later acquired by Shire) in 2015. Its involvement encompasses research, development, manufacturing, and global distribution.

Manufacturing Capabilities: Takeda possesses extensive manufacturing facilities with Good Manufacturing Practices (GMP) compliance, assuring high-quality production of Maribavir. Their facilities in Japan and Europe serve as primary sources.
Global Distribution: Takeda has an established global sales network, facilitating broad availability of Maribavir across North America, Europe, and Asia.
Strategic Significance: As the patent holder and primary supplier, Takeda is the dominant figure controlling raw materials procurement, manufacturing, regulatory approvals, and distribution channels for Maribavir.

2. Contract Manufacturing Organizations (CMOs)

Given the complexities of pharmaceutical manufacturing, Takeda and other pharmaceutical entities often collaborate with Contract Manufacturing Organizations (CMOs) to scale production and meet global demand.

Key CMOs Involved:
- Boehringer Ingelheim: Known for contract manufacturing of antiviral agents, including complex small molecules like Maribavir, leveraging advanced synthesis capabilities.
- Samsung Biologics: Primarily focused on biologics but expanding into small-molecule manufacturing with high-volume capacity.
- Lonza: Offers proprietary manufacturing expertise in complex chemical synthesis, potentially involved in TM production for Maribavir or its intermediates.
Implication: The reliance on CMOs enhances supply flexibility and capacity but requires rigorous quality assurance to meet regulatory standards.

Suppliers of Raw Materials and Active Pharmaceutical Ingredients (APIs)

The production of Maribavir involves synthesis of complex molecules requiring specialized chemical intermediates.

APIs and Intermediates Suppliers:
- China-based Suppliers: Many chemical intermediates used in small-molecule drugs originate from China, with companies like Wuxi AppTec and Zhejiang Medicine providing high-quality APIs.
- India-based Suppliers: Indian chemical manufacturers such as Divi’s Laboratories and Dr. Reddy’s Laboratories supply intermediates and APIs for antiviral drugs, including specialized chemicals used in Maribavir synthesis.
- European and North American Chemical Suppliers: Several companies supply high-purity intermediates and solvents, including Merck KGaA, Thermo Fisher Scientific, and Sigma-Aldrich.
Supply Chain Security: The global nature of chemical sourcing necessitates risk mitigation strategies; geopolitical considerations, quality standards, and freight logistics impact supply continuity.

Distributors and Supply Chain Logistics

Effective distribution channels are vital for ensuring the delivery of Maribavir to healthcare providers and pharmacies globally.

Major Distributors:
- McKesson Corporation: A leading pharmaceutical distributor in North America, authorized by Takeda to supply Maribavir to hospitals and clinics.
- Alliance Healthcare (Now part of the Walgreens Boots Alliance): Distributes to European markets, emphasizing compliance with regional regulations.
- TMG (The Medical Group) and Kong Supermarket: Regional distributors, mainly within Asia and under license arrangements.
Logistics Considerations:
- Cold chain logistics are generally not a concern for Maribavir, but stability during transport and storage adherence to temperature and humidity standards remain critical.
- Strategic warehousing near major healthcare hubs ensures rapid supply and minimizes delays.

Regulatory and Supply Chain Challenges

The supply chain for Maribavir faces several challenges:

Regulatory Approvals: Only a limited number of manufacturers with authorized approval can legally produce and distribute Maribavir, limiting supply flexibility.
Patent and Exclusivity Protections: Takeda holds patent rights, restricting generic or alternative production until patent expiry, which limits the number of suppliers.
Manufacturing Complexity: The complex synthesis route and strict quality control diminish the number of capable manufacturing entities.

Emerging Suppliers and Market Dynamics

With the evolving landscape of antiviral therapies, new entrants are exploring alternative production capacities:

Potential for Biosimilar or Generic Manufacturers: Post-patent expiry, generic manufacturers from India and China might seek approval, diversifying supply sources.
Strategic Alliances: Takeda may establish licensing agreements with regional manufacturers to expand global reach while maintaining quality standards.

Conclusion

The supply ecosystem for Maribavir is concentrated primarily around Takeda Pharmaceutical, which maintains control over manufacturing and distribution channels. Complemented by partnerships with select CMOs and a global network of chemical suppliers and distributors, the supply chain is designed for high standards and reliability. However, geopolitical, regulatory, and patent-related challenges could impact future availability, emphasizing the importance of strategic sourcing and supply chain resilience.

Key Takeaways

Takeda is the primary and most reliable supplier of Maribavir, with comprehensive control over its manufacturing and distribution.
Contract Manufacturing Organizations expand production capacity but require rigorous oversight to maintain quality.
The supply chain relies heavily on a global network of chemical intermediates suppliers, mainly from China, India, and Europe.
Regulatory restrictions and patent protections limit the number of active suppliers, with potential for diversification post-patent expiration.
Pharmaceutical companies and healthcare providers should monitor supply chain developments for risks related to manufacturing capacity, geopolitical factors, and regulatory changes.

FAQs

1. Which companies currently manufacture Maribavir?
Takeda Pharmaceutical is the primary manufacturer of Maribavir, supported by contract manufacturing organizations (CMOs). No significant generic manufacturers are authorized until patent expiration.

2. Are there alternative suppliers for Maribavir’s raw materials?
Yes, suppliers of chemical intermediates and APIs include companies in China (e.g., Wuxi AppTec), India (e.g., Divi’s Laboratories), and Europe (e.g., Merck KGaA). However, these are typically integrated into Takeda's supply chain or licensed manufacturing arrangements.

3. How does Takeda ensure supply chain security for Maribavir?
Takeda employs diversified sourcing of raw materials, partnerships with multiple CMOs, and compliance with international quality standards to sustain supply security.

4. Is there potential for new suppliers to enter the Maribavir market?
Post-patent expiry, generic manufacturing companies from India and China could become suppliers, increasing competition and supply diversification.

5. What are key considerations for healthcare providers sourcing Maribavir?
Providers should verify supplier authenticity, ensure regulatory compliance, and monitor supply chain stability to prevent shortages or quality issues.

References:

[1] Takeda Pharmaceutical. "Maribavir: Product Details." 2022.
[2] U.S. Food and Drug Administration. "Maribavir FDA Approval Documentation," 2021.
[3] Pharmaceutical Technology. "Contract Manufacturing in Pharma: Trends and Key Players," 2022.
[4] Wuxi AppTec. "Chemical Intermediates for Antiviral Drugs," 2023.
[5] Divi’s Laboratories. "API Synthesis Capabilities," 2022.

Suppliers and packagers for generic pharmaceutical drug: MARIBAVIR

MARIBAVIR

Suppliers for the Pharmaceutical Drug: MARIBAVIR